Canakinumab for the treatment of chronic obstructive pulmonary disease

Pulmonary Pharmacology and Therapeutics

Volumn 31, Issue , 2015, Pages 15-27

  Rogliani, Paola ^a   Calzetta, Luigino ^a   Ora, Josuel ^a   Matera, Maria Gabriella ^b  

^a UNIVERSITY OF ROME TOR VERGATA   (Italy)

^b SECOND UNIVERSITY OF NAPLES   (Italy)

Author keywords

Canakinumab; COPD; IL 1 ; Inflammasome; Monoclonal antibody

Indexed keywords

CANAKINUMAB; GELATINASE A; GELATINASE B; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 1ALPHA; INTERLEUKIN 1BETA; INTERLEUKIN 1BETA CONVERTING ENZYME; INTERLEUKIN 8; MACROPHAGE ELASTASE; NUCLEOTIDE BINDING OLIGOMERIZATION DOMAIN LIKE RECEPTOR; TOLL LIKE RECEPTOR 1; TOLL LIKE RECEPTOR 2; TOLL LIKE RECEPTOR 4; TOLL LIKE RECEPTOR 6; AUTACOID; CYTOKINE; INFLAMMASOME; MONOCLONAL ANTIBODY;

ADAPTIVE IMMUNITY; AUTOIMMUNE DISEASE; B LYMPHOCYTE; CHRONIC OBSTRUCTIVE LUNG DISEASE; DENDRITIC CELL; DRUG SAFETY; DRUG TOLERABILITY; HUMAN; INFLAMMATION; INNATE IMMUNITY; LUNG LAVAGE; MACROPHAGE; MORBIDITY; MORTALITY; NEUTROPHIL; NONHUMAN; PRIORITY JOURNAL; REVIEW; RISK FACTOR; SMOKING; T LYMPHOCYTE; AUTOIMMUNE DISEASES; BRONCHOALVEOLAR LAVAGE FLUID; CLINICAL TRIAL (TOPIC); IMMUNOLOGY; METABOLISM; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE;

ANTIBODIES, MONOCLONAL; AUTOIMMUNE DISEASES; BRONCHOALVEOLAR LAVAGE FLUID; CASPASE 1; CLINICAL TRIALS AS TOPIC; CYTOKINES; HUMANS; INFLAMMASOMES; INFLAMMATION; INFLAMMATION MEDIATORS; INTERLEUKIN-1BETA; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE;

EID: 84926285094     PISSN: 10945539     EISSN: 15229629     Source Type: Journal    
DOI: 10.1016/j.pupt.2015.01.005     Document Type: Review

References (87)

1. Lim S.S., Vos T., Flaxman A.D., Danaei G., Shibuya K., Adair-Rohani H., et al. A comparative risk assessment of burden of disease and injury attributable to 67 risk factors and risk factor clusters in 21 regions, 1990-2010: a systematic analysis for the global burden of disease study 2010. Lancet 2012 Dec 15, 380(9859):2224-2260.
2. Brusselle G.G., Joos G.F., Bracke K.R. New insights into the immunology of chronic obstructive pulmonary disease. Lancet 2011, 1015-1026.
3. PJ B. Corticosteroid resistance in airway disease. Proc Am Thorac Soc 2004, 264-268.
4. Celli B.R., MWS Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper. Eur Respir J 2004, 23:932-946.
5. Lachmann H.J., Lowe P., Felix S.D., Rordorf C., Leslie K., Madhoo S., et al. In vivo regulation of interleukin 1beta in patients with cryopyrin-associate periodic syndromes. J Exp Med 2009 May 11, 206(5):1029-1036.
6. David M. Smoking and tobacco control. Monograph 8. Changes in cigarette-related disease risks and their Implication for prevention and control 1997, NIH Publication, No.97:1-1197.
7. Disease GIfCOL Global strategy for the diagnosis, management and prevention of chronic obstructive pulmonary disease 2001, National Heart, Lung and Blood Institute, Bethesda (MD), NHLBI/WHO Workshop Report.
8. Caramori G., Adcock I.M., Di Stefano A., Chung K.F. Cytokine inhibition in the treatment of COPD. Int J Chron Obstruct Pulmon Dis 2014, 9:397-412.
9. Papi A., Bellettato C.M., Braccioni F., Romagnoli M., Casolari P., Caramori G., et al. Infections and airway inflammation in chronic obstructive pulmonary disease severe exacerbations. Am J Respir Crit Care Med 2006 May 15, 173(10):1114-1121.
10. Lofdahl J.M. Different inflammatory cell pattern and macrophage phenotype in chronic obstructive pulmonary disease patients, smokers and non-smokers. Clin Exp Immunol 2006, 428-437.
11. Caramori G., Casolari P., Adcock I. Role of transcription factors in the pathogenesis of asthma and COPD. Cell Commun Adhes 2013, 21-40.
12. Chung K.F., Adcock I.M. Multifaceted mechanisms in COPD: inflammation, immunity, and tissue repair and destruction. Eur Respir J 2008, 31:1334-1356.
13. Sharafkhaneh A., Hanania N.A., Kim V. Pathogenesis of emphysema: from the bench to the bedside. Proc Am Thorac Soc 2008, 5:475-477.
14. Taraseviciene-Stewart L., Voelkel N.F. Molecular pathogenesis of emphysema. JClin Investigation 2008, 118:394-402.
15. Birrell M.A., Eltom S. The role of the NLRP3 inflammasome in the pathogenesis of airway disease. Pharmacol Ther 2011, 130:364-370.
16. Motz G.T., BLE, Wesselkamper S.C., Flury J.L., Borchers M.T. Chronic cigarette smoke exposure generates pathogenic T cells capable of driving copd-like disease in Rag2-/- mice. Am J Respir Crit Care Med 2010, 181:1223-1233.
17. Motz G.T., Eppert B.L., Sun G., Wesselkamper S.C., Linke M.J., Deka R., et al. Persistence of lung CD8 T cell oligoclonal expansions upon smoking cessation in a mouse model of cigarette smoke-induced emphysema. J Immunol 2008 Dec 1, 181(11):8036-8043.
18. Zhou R., Yazdi A.S., Menu P., Tschopp J. Arole for mitochondria in NLRP3 inflammasome activation. Nature 2011, 469:221-225.
19. Ishii K.J., Koyama S., Nakagawa A., Coban C., Akira S. Host innate immune receptors and beyond: making sense of microbial infections. Cell Host Microbe 2008, 3:352-363.
20. Franchi L., McDonald C., Kanneganti T.-D., Amer A., Núñez G. Nucleotide-binding oligomerization domain-like receptors: intracellular pattern recognition molecules for pathogen detection and host defense. JImmunol 2006, 177:3507-3513.
21. Freeman C.M., Martinez F.J., Han M.K., Washko G.R., McCubbrey A.L., Chensue S.W., et al. Lung CD8+ T cells in COPD have increased expression of bacterial TLRs. Respir Res 2013, 14.
22. Lamkanfi M., Dixit V.M. Inflammasomes and their roles in health and disease. Annu Rev Cell Dev Biol 2012, 28:137-161.
23. Blackburn, AMaMR Adenosine signaling in asthma and chronic obstructive pulmonary disease. Curr Opin Pulm Med 2006, 12:54-59.
24. Lommatzsch M., Cicko S., Müller T., Lucattelli M., Bratke K., Stoll P., et al. Extracellular adenosine triphosphate and chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2010 May 1, 181(9):928-934.
25. Mortaz E., B S., Nazary M., Givi M.E., Nijkamp F.P., Folkerts G. ATP in the pathogenesis of lung emphysema. Eur J Pharmacol 2009, 619:92-96.
26. Mason D.R., P B., Muruve D.A. Nucleotide-binding oligomerization domain-like receptors and inflammasomes in the pathogenesis of non-microbial inflammation and diseases. JInnate Immun 2012, 4:16-30.
27. Rovina N., K A., Koulouris N.G. Inflammation and immune response in COPD: where do we stand?. Mediat Inflamm 2013, 2013:413735.
28. C K.F. Cytokines in chronic obstructive pulmonary disease. Eur Respir J 2001, (Suppl 34):50s-59s.
29. Garofalo R., Mei F., Espejo R., Ye G., Haeberle H., Baron S., Ogra P.L., Reyes V.E. Respiratory syncytial virus infection of human respiratory epithelial cells up-regulates class I MHC expression through the induction of IFN-beta and IL-1 alpha. J Immunol 1996 Sep 15, 157(6):2506-2513.
30. Yang G.H. Effects of interleukin-1 beta on DNA synthesis in rat alveolar type II cells in primary culture. Respirology 1999, 4:139-145.
31. Chakraborty A., T S., Rordorf C., Lowe P.J., Floch D., Gram H., et al. Pharmacokinetic and pharmacodynamic properties of canakinumab, a human anti-interleukin-1β monoclonal antibody. Clin Pharmacokinet 2012, 51:e1-e18.
32. Weber A., W P., Kracht M. Interleukin-1 (IL-1) pathway. Sci Signal 2010, 3(105):cm1.
33. Martinon F., M A., Tschopp J. The inflammasomes: guardians of the body. Annu Rev Immunol 2009, 27:229-265.
34. Guma M. Caspase 1-independent activation of interleukin-1beta in neutrophil-predominant inflammation. Arthritis Rheum 2009, 60:3642-3650.
35. Joosten L.A. Inflammatory arthritis in caspase 1 gene-deficient mice: contribution of proteinase 3 to caspase 1-independent production of bioactive interleukin-1beta. Arthritis Rheum 2009, 60:3651-3662.
36. Martinon F., B K., Tschopp J. The inflammasome: a molecular platform triggering activation of inflammatory caspases and processing of proIL-beta. Mol Cell 2002, 10:417-426.
37. Contassot E., Beer H.D., French L.E. Interleukin-1, inflammasomes, autoinflammation and the skin. Swiss Med Wkly 2012, 142:w13590.
38. Duewell P. NLRP3 inflammasomes are required for atherogenesis and activated by cholesterol crystals. Nature 2010, 464. 1357-U7.
39. Lappalainen U. Interleukin-1beta causes pulmonary inflammation, emphysema, and airway remodeling in the adult murine lung. Am J Respir Cell Mol Biol 2005, 32:311-318.
40. Hogmalm A., Backstrom E., Bry M., Lappalainen U., Lukkarinen H.P., Bry K. Role of CXC chemokine receptor-2 in a murine model of bronchopulmonary dysplasia. Am J Respir Cell Mol Biol 2012, 47:746-758.
41. Murugan V., Peck M.J. Signal transduction pathways linking the activation of alveolar macrophages with the recruitment of neutrophils to lungs in chronic obstructive pulmonary disease. Exp lung Res 2009, 35:439-485.
42. Singh M., Lee S.H., Porter P., Xu C., Ohno A., Atmar R.L., et al. Human rhinovirus proteinase 2A induces TH1 and TH2 immunity in patients with chronic obstructive pulmonary disease. J Allergy Clin Immunol 2010 Jun, 125(6):1369-1378. e2.
43. Doz E., Noulin N., Boichot E., Guénon I., Fick L., Le Bert M., et al. Cigarette smoke-induced pulmonary inflammation is TLR4/MyD88 and IL-1R1/MyD88 signaling dependent. J Immunol 2008 Jan 15, 180(2):1169-1178.
44. Churg A., Z S., Wang X., Wang R., Wright J.L. The role of lnterleukin-1 p in murine cigarette smoke-induced emphysema and small airway remodeling. Am J Respir Cell Mol Biol 2009, 40:482-490.
45. Lucey E.C. Severity of elastase-induced emphysema is decreased in tumor necrosis factor alpha and interleukin-1beta receptor-deficient mice. Lab Invest 2002, 82:79-85.
46. Castro P. Inhibition of interleukin-1beta reduces mouse lung inflammation induced by exposure to cigarette smoke. Eur J Pharmacol 2004, 498:279-286.
47. Russell R.E. Release and activity of matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 by alveolar macrophages from patients with chronic obstructive pulmonary disease. Am J Respir Cell Mol Biol 2002, 26:602-609.
48. Wesselius L.J. Rapid lung cytokine accumulation and neutrophil recruitment after lipopolysaccharide inhalation by cigarette smokers and nonsmokers. JLab Clin Med 1997, 129:106-114.
49. Li Y.Q. N-Acetyl-L-cysteine and pyrrolidine dithiocarbamate inhibited nuclear factor-kappaB activation in alveolar macrophages by different mechanisms. Acta Pharmacol Sin 2006, 27:339-346. ea.
50. Dhimolea E. Canakinumab. MAbs 2010, 2:3-13.
51. Alten R., G H., Joosten L.A., van den Berg W.B., Sieper J., Wassenberg S., et al. The human anti-IL-1 beta monoclonal antibody ACZ885 is effective in joint inflammation models in mice and in a proof-of-concept study in patients with rheumatoid arthritis. Arthritis Res Ther 2008, 10:67.
52. Church L.D., M M.F. Canakinumab, a fully-human mAb against IL-1beta for the potential treatment of inflammatory disorders. Curr Opin Mol Ther 2009, 11:81-89.
53. Bonner J., L P., Lowe P., Golor G., Woessner R., Pascoe S. PK/PD, safety and tolerability of a human anti-IL-1B monoclonal antibody (ACZ885) in healthy subjects. Annu Congr Eur Resp Soc 2006, 748.
54. Novartis. Safety, tolerability, pharmacokinetics and pharmacodynamics of ACZ885 in healthy Japanese male volunteers. ClinicalTrialsgov identifier NCT00421226 US National Institutes of Health, ClinicalTrialsgov [online] Available from: URL: . http://wwwclinicaltrialsgov.
55. Ridker P.M., T T., Zalewski A., Libby P. Interleukin-1β inhibition and the prevention of recurrent cardiovascular events: rationale and design of the Canakinumab anti-inflammatory thrombosis outcomes study (CANTOS). Am Heart J 2011, 162:597-605.
56. Hoffman H.M., Rosengren S., Boyle D.L., Cho J.Y., Nayar J., Mueller J.L., et al. Prevention of cold-associated acute inflammation in familial cold autoinflammatory syndrome by interleukin-1 receptor antagonist. Lancet 2004 Nov 13-19, 364(9447):1779-1785.
57. Chakraborty A., Tannenbaum S., Rordorf C., Lowe P.J., Floch D., Gram H., et al. Pharmacokinetic and pharmacodynamic properties of Canakinumab, a human anti-interleukin-1beta monoclonal antibody. Clin Pharmacokinet 2012, 51:e1-18.
58. Simon A., A B., Braun-Falco M., De Koning H., Fermand J.P., Grattan C., et al. Schnitzler's syndrome: diagnosis, treatment, and follow-up. Allergy 2013, 68:562-568. 10.1111/all.12129.
59. Pascual V., Allantaz F., Arce E., Punaro M., Banchereau J. Role of interleukin-1 (IL-1) in the pathogenesis of systemic onset juvenile idiopathic arthritis and clinical response to IL-1 blockade. J Exp Med 2005 May 2, 201(9):1479-1486.
60. Burger D., D J., Palmer G., Gabay C. Is IL-1 a good therapeutic target in the treatment of arthritis?. Best Pract Res Clin Rheumatol 2006, 20:879-896.
61. Rider T.G., J K. The modern management of gout 2010, 49:5-14.
62. Larsen C.M., Faulenbach M., Vaag A., Vølund A., Ehses J.A., Seifert B., et al. Interleukin-1-receptor antagonist in type 2 diabetes mellitus. N Engl J Med 2007 Apr 12, 356(15):1517-1526.
63. Pascoe S., Kanniess F., Bonner J., Lloyd P., Lowe P., Beier J., et al. A monoclonal antibody to IL-1 b attenuates the late asthmatic response to antigen challenge in patients with mild asthma. Paper presented at: ERS Annual Congress; September 3, 2006 2006, Munich, Germany.
64. Novartis. Safety And efficacy of multiple doses of canakinumab (ACZ885) in chronic obstructive pulmonary disease (COPD) patients. ClinicalTrialsgov Identifier: NCT00581945 US National Institutes of Health, ClinicalTrialsgov [online] Available from: URL: accessed August 07, 2014. http://wwwclinicaltrialsgov.
65. Touitou I., K-PI Autoinflammatory diseases. Best Pract Res Clin Rheumatol 2008, 22:811-829.
66. Lachmann H.J., L P., Felix S.D., Rordorf C., Leslie K., Madhoo S., et al. Invivo regulation of interleukin 1beta in patients with cryopyrin- -associated periodic syndromes. JExp Med 2009, 206:1029-1036.
67. Koné-Paut I., L H., Kuemmerle-Deschner J.B., Hachulla E., Leslie K.S., Mouy R., et al. Sustained remission of symptoms and improved health-related quality of life in patients with cryopyrin-associated periodic syndrome treated with canakinumab: results of a double-blind placebo-controlled randomized withdrawal study. Arthritis Res Ther 2011, 13:R202. Canakinumab in CAPS Study Group.
68. Kone-Paut I., Lachmann H.J., Kuemmerle-Deschner J.B., Hachulla E., Leslie K.S., Mouy R., et al. Sustained remission of symptoms and improved health-related quality of life in patients with cryopyrin-associated periodic syndrome treated with canakinumab: results of a double-blind placebo-controlled randomized withdrawal study. Arthritis Res Ther 2011, 13:R202.
69. Kuemmerle-Deschner J.B., Hachulla E., Cartwright R., Hawkins P.N., Tran T.A., Bader-Meunier B., et al. Two-year results from an open-label, multicentre, phase III study evaluating the safety and efficacy of canakinumab in patients with cryopyrin-associated periodic syndrome across different severity phenotypes. Ann Rheum Dis 2011, 70:2095-2102.
70. de Koning H.D., S J., van der Ven-Jongekrijg J., Stoffels M., van der Meer J.W., Simon A. Sustained efficacy of the monoclonal anti-interleukin-1 beta antibody canakinumab in a 9-month trial in Schnitzler's syndrome. Ann Rheum Dis 2013, 72:1634-1638.
71. Vanderschueren S., K D. Canakinumab in schnitzler syndrome. Semin Arthritis Rheum 2013, 42:413-416.
72. Adib N., S A., Thomson W. Outcome following onset of juvenile idiopathic inflammatory arthritis: II. Predictors of outcome in juvenile arthritis. Rheumatol (Oxford) 2005, 44:1002-1007.
73. Ruperto N. Aphase II, multicenter, open-label study evaluating dosing and preliminary safety and efficacy of canakinumab in systemic juvenile idiopathic arthritis with active systemic features. Arthritis Rheum 2012, 64:557-567.
74. Ruperto N. Two randomized trials of canakinumab in systemic juvenile idiopathic arthritis. NEngl J Med 2012, 367:2396-2406.
75. Alten R., G-RJ, Durez P., Beaulieu A., Sebba A., Krammer G., et al. Efficacy and safety of the human anti-IL-1β monoclonal antibody canakinumab in rheumatoid arthritis: results of a 12-week, Phase II, dose-finding study. BMC Musculoskelet Disord 2011 Jul 7, 153.
76. Lee S.J., H J., Terkeltaub R., et al. Perceptions of disease and health-related quality of life among patients with gout. Rheumatol Oxf 2009, 48:582-586.
77. Jordan K.M., Cameron J.S., Snaith M., Zhang W., Doherty M., Seckl J., et al. British Society for Rheumatology and British Health Professionals in Rheumatology Standards, Guidelines and Audit Working Group (SGAWG). British Society for Rheumatology and British Health Professionals in Rheumatology guideline for the management of gout. Rheumatology (Oxford) 2007 Aug, 46(8):1372-1374.
78. Schlesinger N., Mysler E., Lin H.Y., De Meulemeester M., Rovensky J., Arulmani U., et al. Canakinumab reduces the risk of acute gouty arthritis flares during initiation of allopurinol treatment: results of a double-blind, randomised study. Ann Rheum Dis 2011 Jul, 70(7):1264-1271.
79. Schlesinger N., A R., Bardin T., Schumacher H.R., Bloch M., Gimona A., et al. Canakinumab for acute gouty arthritis in patients with limited treatment options: results from two randomised, multicentre, active-controlled, double-blind trials and their initial extensions. Ann Rheum Dis 2012, 71:1839-1848.
80. Moran A. Interleukin-1 antagonism in type 1 diabetes of recent onset: two multicentre, randomised, double-blind, placebo-controlled trials. Lancet 2013, 381:1905-1915.
81. Ridker P.M., H C., Walter V., Everett B., Libby P., Hensen J., et al. CANTOS Pilot investigative Group. Effects of interleukin-1β inhibition with canakinumab on hemoglobin A1c, lipids, C-reactive protein, interleukin-6, and fibrinogen: a phase IIb randomized, placebo-controlled trial. Circulation 2012, 126:2739-2748.
82. Pauwels N.S., B K., Dupont L.L., et al. Role of IL-1α and the Nlrp3/caspase-1/IL-1β axis in cigarette smoke-induced pulmonary inflammation and COPD. Eur Respir J 2011, 38:1019-1028.
83. LLC M. A study to evaluate the efficacy of MEDI8968 in chronic obstructive pulmonary disease (SPRING). ClinicalTrialsgov Identifier: NCT01448850 US National Institutes of Health, ClinicalTrialsgov [online] Available from: URL: [accessed August 07, 2014]. http://wwwclinicaltrialsgov.
84. Dinarello C.A., S A., van der Meer J.W. Treating inflammation by blocking interleukin-1 in a broad spectrum of diseases. Nat Rev Drug Discov 2012, 11:633-652.
85. University VC. Pilot study of the safety and efficacy of anakinra (Recombinant human Interleukin-1 receptor antagonist) in pulmonary Hypertension ClinicalTrialsgov Identifier:NCT01479010 US National Institutes of Health, ClinicalTrialsgov [online] Available from: URL: [accessed August 07, 2014]. http://wwwclinicaltrialsgov.
86. Pharmaceuticals N. Safety, tolerability, and efficacy of AIN457 in patients with Uncontrolled asthma. ClinicalTrialsgov Identifier: NCT01478360 US National Institutes of Health, ClinicalTrialsgov [online] Available from: URL: [accessed August 07, 2014]. http://wwwclinicaltrialsgov.
87. Imagawa T., N R., Takada H., Takeshita S., Pate N., Kim D., et al. Safety and efficacy of canakinumab in Japanese patients with phenotypes of cryopyrin-associated periodic syndrome as established in the first open-label, phase-3 pivotal study (24-week results). Clin Exp Rheumatol 2013;Mar-Apr, 31:302-309.